Page 404 - Williams Hematology ( PDFDrive )

378 Part V: Therapeutic Principles Chapter 23: Hematopoietic Cell Transplantation 379

269. Palumbo A, Cavallo F, Gay F, et al: Autologous transplantation and maintenance ther- 295. Olsson R, Remberger M, Schaffer M, et al: Graft failure in the modern era of allogeneic
apy in multiple myeloma. N Engl J Med 371:895–905, 2014. hematopoietic SCT. Bone Marrow Transplant 48:537–543, 2013.
270. Kumar A, Kharfan-Dabaja MA, Glasmacher A, et al: Tandem versus single autologous 296. Baron F, Maris MB, Storer BE, et al: High doses of transplanted CD34+ cells are asso-
hematopoietic cell transplantation for the treatment of multiple myeloma: A systematic ciated with rapid T-cell engraftment and lessened risk of graft rejection, but not more
review and meta-analysis. J Natl Cancer Inst 101:100–106, 2009. graft-versus-host disease after nonmyeloablative conditioning and unrelated hemato-
271. Attal M, Harousseau JL, Facon T, et al: Single versus double autologous stem-cell trans- poietic cell transplantation. Leukemia 19:822–828, 2005.
plantation for multiple myeloma. N Engl J Med 349:2495–2502, 2003. 297. Schriber J, Agovi MA, Ho V, et al: Second unrelated donor hematopoietic cell trans-
272. Bruno B, Rotta M, Patriarca F, et al: A comparison of allografting with autografting for plantation for primary graft failure. Biol Blood Marrow Transplant 16:1099–1106, 2010.
newly diagnosed myeloma. N Engl J Med 356:1110–1120, 2007. 298. Gyurkocza B, Cao TM, Storb RF, et al: Salvage allogeneic hematopoietic cell transplan-
273. Gahrton G, Iacobelli S, Bjorkstrand B, et al: Autologous/reduced-intensity allogeneic tation with fludarabine and low-dose total body irradiation after rejection of first allog-
stem cell transplantation vs autologous transplantation in multiple myeloma: Long- rafts. Biol Blood Marrow Transplant 15:1314–1322, 2009.
term results of the EBMT-NMAM2000 study. Blood 121:5055–5063, 2013. 299. Vera-Llonch M, Oster G, Ford CM, et al: Oral mucositis and outcomes of allogeneic
274. Giaccone L, Storer B, Patriarca F, et al: Long-term follow-up of a comparison of non- hematopoietic stem-cell transplantation in patients with hematologic malignancies.
myeloablative allografting with autografting for newly diagnosed myeloma. Blood Support Care Cancer 15:491–496, 2007.
117:6721–6727, 2011. 300. Cutler C, Logan B, Nakamura R, et al: Tacrolimus/sirolimus vs tacrolimus/metho-
275. Rosinol L, Perez-Simon JA, Sureda A, et al: A prospective PETHEMA study of tandem trexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood
autologous transplantation versus autograft followed by reduced-intensity condition- 124:1372–1377, 2014.
ing allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112:3591– 301. Goldberg JD, Zheng J, Castro-Malaspina H, et al: Palifermin is efficacious in recipients
3593, 2008. of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell trans-
276. Garban F, Attal M, Michallet M, et al: Prospective comparison of autologous stem plants. Bone Marrow Transplant 48:99–104, 2013.
cell transplantation followed by dose-reduced allograft (IFM99–03 trial) with tandem 302. Nooka AK, Johnson HR, Kaufman JL, et al: Pharmacoeconomic analysis of palifermin
autologous stem cell transplantation (IFM99–04 trial) in high-risk de novo multiple to prevent mucositis among patients undergoing autologous hematopoietic stem cell
myeloma. Blood 107:3474–3480, 2006. transplantation. Biol Blood Marrow Transplant 20:852–857, 2014.
277. Lokhorst HM, van der Holt B, Cornelissen JJ, et al: Donor versus no-donor comparison 303. Levine JE, Blazar BR, DeFor T, et al: Long-term follow-up of a phase I/II randomized,
of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD)
study. Blood 119:6219–6225; quiz 6399, 2012. after related donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood
278. Krishnan A, Pasquini MC, Logan B, et al: Autologous haemopoietic stem-cell trans- Marrow Transplant 14:1017–1021, 2008.
plantation followed by allogeneic or autologous haemopoietic stem-cell transplantation 304. Jagasia MH, Abonour R, Long GD, et al: Palifermin for the reduction of acute GVHD:
in patients with multiple myeloma (BMT CTN 0102): A phase 3 biological assignment A randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant
trial. Lancet Oncol 12:1195–1203, 2011. 47:1350–1355, 2012.
279. Armeson KE, Hill EG, Costa LJ: Tandem autologous vs autologous plus reduced 305. Shulman HM, Fisher LB, Schoch HG, et al: Veno-occlusive disease of the liver after
intensity allogeneic transplantation in the upfront management of multiple myeloma: marrow transplantation: Histological correlates of clinical signs and symptoms. Hepa-
Meta-analysis of trials with biological assignment. Bone Marrow Transplant 48:562– tology 19:1171–1181, 1994.
567, 2013. 306. McCune JS, Batchelder A, Deeg HJ, et al: Cyclophosphamide following targeted oral
280. Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics,
transplantation after failure of conventional chemotherapy in adults with intermediate- liver toxicity, and mortality. Biol Blood Marrow Transplant 13:853–862, 2007.
grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 316:1493–1498, 1987. 307. McCune JS, Batchelder A, Guthrie KA, et al: Personalized dosing of cyclophosphamide
281. Yuen AR, Rosenberg SA, Hoppe RT, et al: Comparison between conventional salvage in the total body irradiation-cyclophosphamide conditioning regimen: A phase II trial
therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s in patients with hematologic malignancy. Clin Pharmacol Ther 85:615–622, 2009.
disease. Blood 89:814–822, 1997. 308. Wong KM, Atenafu EG, Kim D, et al: Incidence and risk factors for early hepatotox-
282. Moskowitz AJ, Yahalom J, Kewalramani T, et al: Pretransplantation functional imag- icity and its impact on survival in patients with myelofibrosis undergoing allogeneic
ing predicts outcome following autologous stem cell transplantation for relapsed and hematopoietic cell transplantation. Biol Blood Marrow Transplant 18:1589–1599, 2012.
refractory Hodgkin lymphoma. Blood 116:4934–4937, 2010. 309. McKoy JM, Angelotta C, Bennett CL, et al: Gemtuzumab ozogamicin-associated sinu-
283. Terasawa T, Dahabreh IJ, Nihashi T: Fluorine-18-fluorodeoxyglucose positron emission soidal obstructive syndrome (SOS): An overview from the research on adverse drug
tomography in response assessment before high-dose chemotherapy for lymphoma: A events and reports (RADAR) project. Leuk Res 31:599–604, 2007.
systematic review and meta-analysis. Oncologist 15:750–759, 2010. 310. Wadleigh M, Richardson PG, Zahrieh D, et al: Prior gemtuzumab ozogamicin exposure
284. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation significantly increases the risk of veno-occlusive disease in patients who undergo mye-
as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non loablative allogeneic stem cell transplantation. Blood 102:1578–1582, 2003.
-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545, 1995. 311. Carreras E, Diaz-Beya M, Rosinol L, et al: The incidence of veno-occlusive disease fol-
285. Gisselbrecht C, Glass B, Mounier N, et al: Salvage regimens with autologous transplan- lowing allogeneic hematopoietic stem cell transplantation has diminished and the out-
tation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184– come improved over the last decade. Biol Blood Marrow Transplant 17:1713–1720, 2011.
4190, 2010. 312. Ohashi K, Tanabe J, Watanabe R, et al: The Japanese multicenter open randomized trial
286. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemo- of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell
therapy followed by autologous stem cell transplantation in first remission significantly transplantation. Am J Hematol 64:32–38, 2000.
prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective 313. Ruutu T, Eriksson B, Remes K, et al: Ursodeoxycholic acid for the prevention of hepatic
randomized trial of the European MCL Network. Blood 105:2677–2684, 2005. complications in allogeneic stem cell transplantation. Blood 100:1977–1983, 2002.
287. LaCasce AS, Vandergrift JL, Rodriguez MA, et al: Comparative outcome of initial ther- 314. McDonald GB, Hinds MS, Fisher LD, et al: Veno-occlusive disease of the liver and mul-
apy for younger patients with mantle cell lymphoma: An analysis from the NCCN NHL tiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann
Database. Blood 119:2093–2099, 2012. Intern Med 118:255–267, 1993.
288. Fenske TS, Zhang MJ, Carreras J, et al: Autologous or reduced-intensity conditioning 315. Coppell JA, Richardson PG, Soiffer R, et al: Hepatic veno-occlusive disease following
allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell stem cell transplantation: Incidence, clinical course, and outcome. Biol Blood Marrow
lymphoma: Analysis of transplantation timing and modality. J Clin Oncol 32:273–281, Transplant 16:157–168, 2010.
2014. 316. Bearman SI, Anderson GL, Mori M, et al: Venoocclusive disease of the liver: Develop-
289. Cohen JB, Geyer SM, Lozanski G, et al: Complete response to induction therapy in ment of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol
patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with 11:1729–1736, 1993.
prolonged progression-free survival. Cancer 120:1677–1685, 2014. 317. Echart CL, Graziadio B, Somaini S, et al: The fibrinolytic mechanism of defibrotide:
290. Petrich AM, Gandhi M, Jovanovic B, et al: Impact of induction regimen and stem cell Effect of defibrotide on plasmin activity. Blood Coagul Fibrinolysis 20:627–634, 2009.
transplantation on outcomes in double-hit lymphoma: A multicenter retrospective 318. Richardson PG, Soiffer RJ, Antin JH, et al: Defibrotide for the treatment of severe
analysis. Blood 124:2354–2361, 2014. hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation:
291. Burroughs LM, O’Donnell PV, Sandmaier BM, et al: Comparison of outcomes of HLA- A multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 16:1005–
matched related, unrelated, or HLA-haplo-identical related hematopoietic cell trans- 1017, 2010.
plantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin 319. Panoskaltsis-Mortari A, Griese M, Madtes DK, et al: An official American Thoracic
lymphoma. Biol Blood Marrow Transplant 14:1279–1287, 2008. Society research statement: Noninfectious lung injury after hematopoietic stem
292. Rezvani AR, Norasetthada L, Gooley T, et al: Non-myeloablative allogeneic haemato- cell transplantation: Idiopathic pneumonia syndrome. Am J Respir Crit Care Med
poietic cell transplantation for relapsed diffuse large B-cell lymphoma: A multicentre 183:1262–1279, 2011.
experience. Br J Haematol 143:395–403, 2008. 320. Weiner RS, Horowitz MM, Gale RP, et al: Risk factors for interstitial pneumonia follow-
293. Kohrt H, Lowsky R: Nonmyeloablative conditioning with total lymphoid irradiation ing bone marrow transplantation for severe aplastic anaemia. Br J Haematol 71:535–
and antithymocyte globulin: An update. Curr Opin Hematol 16:460–465, 2009. 543, 1989.
294. Pottinger B, Walker M, Campbell M, et al: The storage and re-infusion of autologous 321. Tizon R, Frey N, Heitjan DF, et al: High-dose corticosteroids with or without etaner-
blood and BM as back-up following failed primary hematopoietic stem-cell transplan- cept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow
tation: A survey of European practice. Cytotherapy 4:127–135, 2002. Transplant 47:1332–1337, 2012.

Kaushansky_chapter 23_p0353-0382.indd 379 9/19/15 12:47 AM